

Huntington's Disease and Vertex Pharmaceuticals

Michael Liu Ph.D 2010 Huntington's Disease Society of America *Potential new therapies for HD session* June 26th 2010



Overview

- Background on Vertex Pharmaceuticals
- Why is Vertex interested in Huntington's Disease?
- The Vertex approach for HD



Vertex Pharmaceuticals Incorporated Small molecule drugs for serious diseases

- Founded in 1989
- 1300+ employees
- 5 R&D sites with stand-alone drug discovery capabilities



Cambridge, MA

Immune Mediated Inflammatory Diseases Anti-infectives Cancer Biochemistry, Biomarkers Clinical Development Pharmaceutical Development & Operations



San Diego, CA Pain, Cystic Fibrosis & Huntington's disease HTS Screening and Automation



Laval, Canada Anti-infectives




Milton Park, UK X-ray Crystallography Immune Mediated Inflammatory Diseases Cancer

Coralville, IA

Tuberculosis Anti-microbials Clinical Virology



Vertex Development Pipeline



Successful collaboration with CFF to develop therapeutics for cystic fibrosis

- Collaboration between Vertex and the Cystic Fibrosis Foundation (1998)
 - Building high-throughput screens
- By 2007, two Vertex compounds in clinical trials
 - May 2008: VX-770 showed clinical efficacy in CF patients
 - Feb 2010: VX-809 showed effect on clinical biomarker in CF patients
 - 2 compounds demonstrated proof-of-concept for correcting molecular defect
- First-in-class therapeutics with potential to modify the disease course and not just treat symptoms





Similarities between CF and HD


	Cystic fibrosis	Huntington's disease
Inherited disease	Yes (single gene)	Yes (single gene)
Unmet medical need	High	High
Disease modifying therapies possible	Yes	Yes
Patient size	30,000 in US	30,000 in US
Volunteer health org and advocacy base	Strong	Strong

Goal: Utilize our experience in CF to serve as a blueprint for HD drug discovery efforts




Overview of the Vertex HD Program

- <u>Goal</u>: Develop <u>disease modifying therapies</u> that delay the onset and progression of Huntington's Disease and improve the quality of patients' lives
- Focused on two scientific approaches to potential therapeutics for HD
 - directly targeting the core defect
 - Neuro-repair





Vertex and HD: Moving forward



- Attacking HD by focusing on disease modifying therapies
- Building networks with scientific and clinical experts in the field of HD
- Commitment to translating scientific breakthroughs into improved patient care

